Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Approved GLP-1 RAs: Indications and Administration Dulaglutide (Trulicity) (injection weekly) Type 2 Diabetes Exenatide extended-release (Bydureon bcise) (injection weekly) Type 2 Diabetes Exenatide (Byetta) (injection twice daily) Type 2 Diabetes Semaglutide (Ozempic) (injection weekly) Type 2 Diabetes Liraglutide (Victoza, Saxenda) (injection daily) Obesity and Type 2 Diabetes, Respectively Lixisenatide (Adlyxin) (injection daily) Type 2 Diabetes Semaglutide (Rybelsus) (taken by mouth once daily) Obesity Semaglutide (Wegovy) (injection weekly) Obesity Tirzepatide* (Mounjaro, Zepbound)(injection weekly) Type 2 Diabetes and Obesity, Respectively View the FDAs up-to-date list of approved GLP-1 RAs Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Patients with T2D 2 to 4 times more likely to develop cardiovascular disease (CVD) than those without T2D
Benefit: Unlike full HGH, it does not affect blood sugar or IGF-1 levels
When discontinuing GLP, a gradual tapering off is typically recommended rather than abruptly stopping
The medullary thyroid carcinoma warning All GLP-1 receptor agonists carry a black-box warning, the most serious warning the FDA issues, regarding thyroid C-cell tumors
317 Lebrun et al
US$ 29.24
US$ 29.24
US$ 29.63
US$ 20.02
